A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study

Published:2017-06-18 Issue:10 Volume:83 Page:2259-2265
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Yuan Guosheng¹^ORCID,Hu Chengguang¹,Zhou Yuchen²,Liu Junwei¹,Huang Huaping¹,Li Yuan¹,Yang Dinghua²,Zhou Fuyuan¹,Zhang Yong-Yuan³,Zhou Yuanping¹

Affiliation:

1. Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital; Southern Medical University; Guangzhou China

2. Department of Hepatobiliary Surgery, Nanfang Hospital; Southern Medical University; Guangzhou China

3. HBVtech, Germantown; Maryland USA

Funder

Chinese Foundation for Hepatitis Prevention and Control of the WBN Research Foundation

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13330/fullpdf

Reference21 articles.

1. Comparison of the efficacy of lamivudine plus adefovir versus entecavir in the treatment of lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis;Huang;Clin Ther,2013

2. Lamivudine for patients with chronic hepatitis B and advanced liver disease;Liaw;N Engl J Med,2004

3. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study;Maklad;Arab J Gastroenterol,2014

4. Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance;Lee;Liver Int,2013

5. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B;Kang;J Clin Gastroenterol,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the treatment of chronic hepatitis B infection: a systematic review and meta-analysis;Annals of Translational Medicine;2022-09

2. Multiple drug-resistant HBV mutation may contribute to poor response of adefovir plus entecavir in entecavir-resistant patients;J INFECT DEV COUNTR;2021

3. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis;Hepatobiliary & Pancreatic Diseases International;2020-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3